Heptazine is a nitrogen-rich, aromatic heterocycle that has gained significant attention in materials science due to its exceptional properties. It is composed of seven nitrogen atoms and six carbon atoms arranged in a heptagonal ring system. Heptazine-based materials exhibit remarkable thermal stability, high surface area, and excellent electronic conductivity, making them suitable for applications in various fields, including catalysis, energy storage, and optoelectronics.
Synthesis of heptazine derivatives often involves condensation reactions of precursors like melamine or cyanuric chloride. These reactions typically take place under high-temperature conditions, leading to the formation of polymeric structures with extended heptazine networks.
Heptazine-based materials have shown promising catalytic activity in various reactions, including oxidation, reduction, and photocatalysis. Their unique electronic structure and high surface area enable them to efficiently adsorb reactants and facilitate catalytic processes.
In the realm of energy storage, heptazine materials have emerged as potential electrode materials for batteries and supercapacitors. Their high electronic conductivity and large surface area allow for rapid charge transfer and high energy storage capacity.
Furthermore, heptazine-based materials exhibit tunable optical properties, making them attractive for applications in optoelectronics. Their ability to absorb and emit light at specific wavelengths has led to their exploration in areas such as organic light-emitting diodes (OLEDs) and solar cells.
The importance of heptazine lies in its versatility and potential to address critical challenges in various fields. Its exceptional thermal stability, high surface area, and electronic conductivity make it a promising building block for advanced materials with wide-ranging applications. The ongoing research in this field aims to further understand and tailor the properties of heptazine-based materials for specific applications, paving the way for novel and impactful technological advancements.'
heptazine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 15950 |
| CHEBI ID | 82225 |
| SCHEMBL ID | 133242 |
| MeSH ID | M0494261 |
| Synonym |
|---|
| unii-wsp2g0yl9n |
| wsp2g0yl9n , |
| 1,3,5-triazine-2,4-diamine, 6-chloro-n,n-diethyl-n'-(1-methylethyl)- |
| nsc-163047 |
| 2-chloro-4-(diethylamino)-6-(isopropylamino)-s-triazine |
| s-triazine, 2-chloro-4-(diethylamino)-6-(isopropylamino)- |
| g 30031 |
| geigy |
| 1,5-triazine-2,4-diamine, 6-chloro-n,n-diethyl-n'-(1-methylethyl)- |
| gesabal |
| heptazine |
| wln: t6n cn enj fmy1&1 dn2&2 fg |
| nsc163047 |
| 1912-25-0 |
| isodiazine |
| ipazine |
| ipazine [iso] |
| ai3-60362 |
| brn 0655694 |
| nsc 163047 |
| caswell no. 187b |
| epa pesticide chemical code 263300 |
| 6-chloro-2-n,2-n-diethyl-4-n-propan-2-yl-1,3,5-triazine-2,4-diamine |
| C19103 |
| AKOS012164696 |
| 6-chloro-n,n-diethyl-n'-(1-methylethyl)-1,3,5-triazine-2,4-diamine |
| 1,3,5-triazine-2,4-diamine, 6-chloro-n2,n2-diethyl-n4-(1-methylethyl)- |
| g-30031 |
| geigy-30,031 |
| 6-chloro-n(sup 2),n(sup 2)-diethyl-n(sup 4)-isopropyl-1,3,5-triazine-2,4-diamine |
| 2-chloro-4-isopropylamino-6-diethylamino-1,3,5-triazine |
| SCHEMBL133242 |
| CHEBI:82225 |
| OWYWGLHRNBIFJP-UHFFFAOYSA-N |
| 6-chloro-n2,n2-diethyl-n4-isopropyl-1,3,5-triazine-2,4-diamine |
| DTXSID8042056 |
| Q27155819 |
| 2-(n,n-diethylamino)-4-(-n-isopropylamino)-6-chloro-1,3,5-triazine |
| Class | Description |
|---|---|
| 1,3,5-triazines | Any compound with a 1,3,5-triazine skeleton, in which nitrogen atoms replace carbon at positions 1, 3 and 5 of the core benzene ring structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||